利尿剂治疗心力衰竭的研究现状被引量：10

Research status of diuretics in the treatment of heart failure

下载PDF

导出

摘要心力衰竭是各种心血管疾病的终末阶段,主要表现为呼吸困难、体力活动受限和体液潴留。在心力衰竭治疗的药物中,利尿剂是唯一能够缓解患者水钠潴留的药物,是心力衰竭治疗中必不可少的组成部分,合理使用利尿剂是心力衰竭治疗取得成功的关键因素。 Heart failure is the terminal stage of various cardiovascular diseases,mainly characterized by dyspnea,limited physical activity and fluid retention.In the drug treatment of heart failure,diuretics are the only way to alleviate water and sodium retention in patients,as an indispensable part in treatment of heart failure,rational use of diuretics is a key factor in the successful treatment of heart failure.

作者聂秋平刘美霞 Nie Qiuping;Liu Meixia(Department of Cardiovascular Medicine,Hebei General Hospital,Shijiazhuang 050000,China)

机构地区河北省人民医院心血管内科

出处《中国心血管杂志》 2018年第5期429-432,共4页 Chinese Journal of Cardiovascular Medicine

关键词心力衰竭利尿剂利尿剂抵抗 Heart failure Diuretics Diuretic resistance

分类号 R541.6 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献8

1赵宇亮,张凌,杨莹莹,唐怡,刘芳,付平.超滤和利尿治疗失代偿性心力衰竭疗效比较的荟萃分析[J].中华医学杂志,2013,93(30):2345-2350. 被引量：7
2齐欣.利尿剂在高血压治疗中的过去、现在和未来[J].中国心血管杂志,2017,22(1):12-13. 被引量：7
3崔炜.心力衰竭患者利尿剂抵抗的处理策略[J].中国心血管杂志,2015,20(1):1-3. 被引量：26
4Theodosios D Filippatos,Moses S Elisaf.Hyponatremia in patients with heart failure[J].World Journal of Cardiology,2013,5(9):317-328. 被引量：13
5中国心力衰竭诊断和治疗指南2014[J].中华心血管病杂志,2014,42(2):98-122. 被引量：4662
6王爱华,廖荣宏,王静.呋塞米联合小剂量多巴胺治疗失代偿性心力衰竭的Meta分析[J].重庆医学,2016,45(14):1934-1936. 被引量：23
7喻文,罗红敏.对严重急性心力衰竭住院患者持续静脉输注或间断静脉推注袢利尿剂：哪一种策略更优？[J].中华危重病急救医学,2015,27(3):208-208. 被引量：4
8朱丁季,刘长华,许顶立.心力衰竭患者利尿剂抵抗及其防治[J].中华心血管病杂志,2015,43(3):200-202. 被引量：31

二级参考文献123

1Metra M, Davison B, Bettari L, et aI. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circ Heart Fail, 2012, 5 :54-62.
2Ronco C, Cicoira M, McCullough PA. Cardiorenal syndrome type I: pathophysiological crosstalk leading to combined heart and kidney dysfunction in the setting of acutely decompensated heart failure.J Am Coli Cardiol, 2012, 60:1031-1042.
3Dickstein K, Cohen-Solal A, Filippatos G, et aI. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collahoration with the Heart Failure Association of the ESC (HF A) and endorsed by the European Society of Intensive Care Medicine (ESICM). EurJ Heart Fail, 2008, 10 :933-989.
4Weber KT. Furosemide in the long-term management of heart failure: the good, the bad, and the uncertain.J Am Coli Cardiol, 2004,44:1308-1310.
5Hunt SA, Abraham WT, Chin MH, et al. 2009 Focused update incorporated into the ACC/ AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundationl American Heart Association Task Force on Practice Guidelines Developed in Collahoration With the International Society for Heart and Lung Transplantation.J Am Coli Cardiol, 2009, 53: e1-e90.
6Costanzo MR, Saltzberg M, 0' SullivanJ, et al. Early ultrafiltration in patients with decompensated heart failure and diuretic resistance.J Am Coli Cardiol, 2005, 46 :2047-2051.
7Giglioli C, Landi D, Cecchi E, et al. Effects of ULTRAfiltration vs. DlureticS on clinical, biohumoral and haemodynamic variables in patients with deCOmpensated heart failure: the ULTRADISCO study. EurJ Heart Fail, 2011, 13 :337-346.
8Costanzo MR, Saltzberg MT,Jessup M, et al. Ultrafiltration is associated with fewer rehospitalizations than continuous diuretic infusion in patients with decompensated heart failure: results from UNLOAD.J Card Fail, 2010,16:277-284.
9Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in Decompensated Heart Failure with Cardiorenal Syndrome. N EnglJ Med, 2012, 367 :2296-2304.
10Badawy SS, F ahmy A. Efficacy and cardiovascular tolerability of continuous veno-venous hemodiafiltration in acute decompensated heart failure: a randomized comparative study.J Crit Care, 2012, 27 :106 e107-e113.